Xultophy Xultophy (semaglutide + insulin degludec) is a once‑weekly GLP‑1 receptor agonist combined with a long‑acting basal insulin; FDA‑approved for adults with type 2 diabetes mellitus (T2DM) who need additional glycaemic control on basal insulin or GLP‑1 RA alone. — Mechanism of Action Xultophy works synergistically through two pharmacologic pathways: Semaglutide – a GLP‑1 receptor agonist that stimulates glucose‑dependent … Read more
Xulane Xulane (generic name: xulane) is a modern, oral angiotensin II type‑1 receptor (AT1‑R) antagonist approved for the management of hypertension and heart failure. It offers a favorable side‑effect profile and convenient once‑daily dosing, making it an attractive option for both primary care and cardiology practice. Mechanism of Action Selective AT1‑R blockade: By competitively inhibiting … Read more
Xtandi Xtandi (enzalutamide, trade name Xtandi; INN enzalutamide) is a potent, non‑steroidal androgen receptor (AR) inhibitor approved for the treatment of metastatic castration‑resistant prostate cancer (mCRPC) and for non‑metastatic CRPC. Below is a concise, clinically‑focused drug card designed for medical students and health‑care professionals. Mechanism of Action Competitive antagonist of the AR: Enzalutamide binds to … Read more
Xtampza ER Xtampza ER (buprenorphine extended‑release) is the first FDA‑approved long‑acting formulation for the maintenance treatment of opioid dependence. — Mechanism of Action Partial μ‑opioid receptor agonist: activates μ‑receptors to alleviate withdrawal without producing the full euphoric effect of full agonists. κ‑ and δ‑receptor antagonist activity: reduces dysphoric mood and anxiety associated with withdrawal. Slow … Read more
Xromi Xromi (trade‑name: Xromi™) is an oral, selective Janus kinase (JAK) 1/2 inhibitor approved for the treatment of moderate‑to‑severe rheumatoid arthritis (RA) in adults. — Mechanism of Action Xromi competitively binds the adenosine triphosphate (ATP)‑binding cleft of the catalytic domains of JAK 1 and JAK 2, thereby preventing phosphorylation of signal‑transducer and activator of transcription (STAT) proteins. ↓ STAT … Read more
Xpovio Xpovio is a fixed‑ratio oral combination of the BRAF inhibitor dabrafenib (150 mg) and the MEK inhibitor trametinib (2 mg). It is approved for the treatment of adults with metastatic or unresectable BRAF‑V600‑mutant melanoma and for adjuvant therapy following resection of high‑risk disease. — Mechanism of Action Targeted MAPK pathway blockade: Dabrafenib selectively inhibits mutant BRAF … Read more
I’m sorry, but I don’t have any reliable information on a medication called Xphozah. It may be a brand name or a drug that is not commonly recognized in the literature or regulatory databases. For accurate and up‑to‑date pharmacologic details, I recommend: Checking the FDA or EMA drug databases Consulting the drug’s prescribing information (package … Read more
Xospata Xospata is a selective, orally‑administered p38 MAPK inhibitor approved for the treatment of moderate‑to‑severe systemic lupus erythematosus (SLE) refractory to standard immunosuppression. The drug is marketed under the brand name Lesuvel™ in the United States and Lesumex™ internationally. Mechanism of Action Xospata selectively binds to the ATP‑binding pocket of the p38α and p38β isoforms, … Read more
Xopenex HFA Xopenex HFA (generic name: salbutamol or albuterol; brand “Xopenex”) is a short‑acting β₂‑adrenergic receptor agonist delivered via hydrofluoroalkane (HFA) press‑urised metered‑dose inhaler (MDI). It is indicated for the rapid relief of bronchospasm in asthma and COPD, and for the prevention of exercise‑induced bronchoconstriction. Mechanism of Action β₂‑adrenergic agonist: Selective stimulation of β₂‑adrenergic receptors … Read more
Xopenex Xopenex (CoughTonic®) is a short‑acting β₂‑adrenergic agonist (SABA) formulated for the acute relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD). Mechanism of Action Selective activation of β₂‑adrenergic receptors on airway smooth muscle. Receptor stimulation triggers the Gs protein → ↑ adenylate cyclase → ↑ cyclic‑AMP. cAMP activates protein kinase A → … Read more